Literature DB >> 16647758

Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.

Bernd J Zünkler1.   

Abstract

Torsades de pointes (TdP) arrhythmia is a potentially fatal form of ventricular arrhythmia that occurs under conditions where cardiac repolarization is delayed (as indicated by prolonged QT intervals from electrocardiographic recordings). A likely mechanism for QT interval prolongation and TdP arrhythmias is blockade of the rapid component of the cardiac delayed rectifier K+ current (IKr), which is encoded by human ether-a-go-go-related gene (HERG). Over 100 non-cardiovascular drugs have the potential to induce QT interval prolongations in the electrocardiogram (ECG) or TdP arrhythmias. The binding site of most HERG channel blockers is located inside the central cavity of the channel. An evaluation of possible effects on HERG channels during the development of novel drugs is recommended by international guidelines. During cardiac ischaemia activation of ATP-sensitive K+ (KATP) channels contributes to action potential (AP) shortening which is either cardiotoxic by inducing re-entrant ventricular arrhythmias or cardioprotective by inducing energy-sparing effects or ischaemic preconditioning (IPC). KATP channels are formed by an inward-rectifier K+ channel (Kir6.0) and a sulfonylurea receptor (SUR) subunit: Kir6.2 and SUR2A in cardiac myocytes, Kir6.2 and SUR1 in pancreatic beta-cells. Sulfonylureas and glinides stimulate insulin secretion via blockade of the pancreatic beta-cell KATP channel. Clinical studies about cardiotoxic effects of sulfonylureas are contradictory. Sulfonylureas and glinides differ in their selectivity for pancreatic over cardiovascular KATP channels, being either selective (tolbutamide, glibenclamide) or non-selective (repaglinide). The possibility exists that non-selective KATP channel inhibitors might have cardiovascular side effects. Blockers of the pore-forming Kir6.2 subunit are insulin secretagogues and might have cardioprotective or cardiotoxic effects during cardiac ischaemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647758     DOI: 10.1016/j.pharmthera.2006.03.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  16 in total

Review 1.  Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies.

Authors:  Nancy J Brown
Journal:  J Am Soc Hypertens       Date:  2012-03-19

2.  Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.

Authors:  Charles E Leonard; Colleen M Brensinger; Christina L Aquilante; Warren B Bilker; Denise M Boudreau; Rajat Deo; James H Flory; Joshua J Gagne; Margaret J Mangaali; Sean Hennessy
Journal:  Diabetes Care       Date:  2018-02-02       Impact factor: 19.112

Review 3.  Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.

Authors:  James H Flory; Jenny K Ukena; James S Floyd
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

Review 4.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

5.  Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.

Authors:  Ruth Dixon; Sarah Job; Ruth Oliver; Debra Tompson; John G Wright; Kay Maltby; Ulrike Lorch; Jorg Taubel
Journal:  Br J Clin Pharmacol       Date:  2008-07-23       Impact factor: 4.335

6.  Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.

Authors:  Yan Long; Zuoxian Lin; Menghang Xia; Wei Zheng; Zhiyuan Li
Journal:  Toxicol Appl Pharmacol       Date:  2013-01-08       Impact factor: 4.219

7.  Blockade of HERG K+ channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells.

Authors:  Dong-fang Gu; Xue-lian Li; Zhi-ping Qi; Sha-shan Shi; Mei-qin Hu; Dong-min Liu; Cheng-bai She; Yan-jie Lv; Bao-xin Li; Bao-feng Yang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-05-08       Impact factor: 3.000

8.  Electrophysiological and fluorescence microscopy studies with HERG channel/EGFP fusion proteins.

Authors:  Sonja Claassen; Sarah Schwarzer; Jost Ludwig; Bernd J Zünkler
Journal:  J Membr Biol       Date:  2008-03       Impact factor: 1.843

9.  A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.

Authors:  Steven A Titus; Daniel Beacham; Sampada A Shahane; Noel Southall; Menghang Xia; Ruili Huang; Elizabeth Hooten; Yong Zhao; Louie Shou; Christopher P Austin; Wei Zheng
Journal:  Anal Biochem       Date:  2009-07-05       Impact factor: 3.365

10.  A novel hydroxyfuroic acid compound as an insulin receptor activator. Structure and activity relationship of a prenylindole moiety to insulin receptor activation.

Authors:  Henry J Tsai; Shan-Yen Chou
Journal:  J Biomed Sci       Date:  2009-07-30       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.